Skip to main content
Erschienen in: Neurocritical Care 1/2017

21.03.2017 | Original Article

Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review

verfasst von: Sung M. Cho, Nader Moazami, Jennifer A. Frontera

Erschienen in: Neurocritical Care | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Ischemic stroke and intracranial hemorrhage (ICH) following left ventricular assist device (LVAD) placement are major causes of morbidity. The incidence and mortality associated with these events stratified by device type have not been systematically explored.

Methods

A systematic review of PubMed was conducted from January 2007 through June 2016 for all English-language articles involving HeartMate II (HMII) and HeartWare LVAD patients. Ischemic stroke and/or ICH incidence (events per patient-year) and associated mortality rates were abstracted for each device type.

Results

Of 735 articles reviewed, 48 (11,310 patients) met inclusion criteria (33 HMII, six HeartWare, eight both devices, and one unspecified). The median duration of device support was 112 days (total 13,723 patient-years). Overall, ischemic stroke or ICH occurred in 9.8% (1110 persons and 0.08 events per patient year [EPPY]). Ischemic stroke occurred in a median of 6.0% or 0.06 EPPY (range 0–16% or 0–0.21 EPPY) of HMII patients versus 7.5% or 0.09 EPPY (range 4–17.1% or 0.01–0.94 EPPY) of HeartWare patients. ICH occurred in a median of 3.0% or 0.04 EPPY (range 0–13.5% or 0–0.13 EPPY) of HMII and 8.0% or 0.08 EPPY (range 3–23% or 0.01–0.56 EPPY) of HeartWare patients. The median mortality rate for LVAD-associated ischemic stroke was 31% (HMII: 33%, [range 2.4–75%] and HeartWare: 11.5% [range 3.9–40%]), and the median mortality rate following ICH was 71% (HMII: 75%, [range 3.9–100%] and HeartWare: 44%, [range 3.1–88%]).

Conclusions

Ischemic stroke and ICH are common after LVAD placement, but heterogeneous event rates are reported in the literature. Given the high associated mortality, further prospective study is warranted.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;128:1810–52.CrossRefPubMed Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2013;128:1810–52.CrossRefPubMed
2.
Zurück zum Zitat Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transpl. 2015;34:1495–504.CrossRef Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transpl. 2015;34:1495–504.CrossRef
3.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMed Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.CrossRefPubMed
5.
Zurück zum Zitat Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefPubMed Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.CrossRefPubMed
6.
Zurück zum Zitat Karimi A, Beaver TM, Hess PJ, Martin TD, Staples ED, Schofield RS, et al. Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II recipients. Interact CardioVasc Thorac Surg. 2014;18:457–65.CrossRefPubMedPubMedCentral Karimi A, Beaver TM, Hess PJ, Martin TD, Staples ED, Schofield RS, et al. Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II recipients. Interact CardioVasc Thorac Surg. 2014;18:457–65.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Teuteberg JJ, Slaughter MS, Rogers JG, McGee EC, Pagani FD, Gordon R, et al. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies. JACC Heart Fail. 2015;3:818–28.CrossRefPubMed Teuteberg JJ, Slaughter MS, Rogers JG, McGee EC, Pagani FD, Gordon R, et al. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies. JACC Heart Fail. 2015;3:818–28.CrossRefPubMed
8.
Zurück zum Zitat Wilson TJ, Stetler WR, Al-Holou WN, Sullivan SE, Fletcher JJ. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118:1063–8.CrossRefPubMed Wilson TJ, Stetler WR, Al-Holou WN, Sullivan SE, Fletcher JJ. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118:1063–8.CrossRefPubMed
9.
Zurück zum Zitat Lalonde SD, Alba AC, Rigobon A, Ross HJ, Delgado DH, Billia F, et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg. 2013;28:604–10.CrossRefPubMed Lalonde SD, Alba AC, Rigobon A, Ross HJ, Delgado DH, Billia F, et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg. 2013;28:604–10.CrossRefPubMed
10.
Zurück zum Zitat Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, et al. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transpl. 2016;35:1003–9.CrossRef Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, et al. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transpl. 2016;35:1003–9.CrossRef
11.
Zurück zum Zitat McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD, Allen LA. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. Circ Heart Fail. 2014;7:1003–13.CrossRefPubMedPubMedCentral McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD, Allen LA. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. Circ Heart Fail. 2014;7:1003–13.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151:177–89.CrossRefPubMed Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: a multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg. 2016;151:177–89.CrossRefPubMed
13.
Zurück zum Zitat Coffin ST, Haglund NA, Davis ME, Xu M, Dunlay SM, Cowger JA, et al. Adverse neurologic events in patients bridged with long-term mechanical circulatory support: a device-specific comparative analysis. J Heart Lung Transpl. 2015;34:1578–85.CrossRef Coffin ST, Haglund NA, Davis ME, Xu M, Dunlay SM, Cowger JA, et al. Adverse neurologic events in patients bridged with long-term mechanical circulatory support: a device-specific comparative analysis. J Heart Lung Transpl. 2015;34:1578–85.CrossRef
14.
Zurück zum Zitat Morris AA, Pekarek A, Wittersheim K, Cole RT, Gupta D, Nguyen D, et al. Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. J Heart Lung Transpl. 2015;34:1570–7.CrossRef Morris AA, Pekarek A, Wittersheim K, Cole RT, Gupta D, Nguyen D, et al. Gender differences in the risk of stroke during support with continuous-flow left ventricular assist device. J Heart Lung Transpl. 2015;34:1570–7.CrossRef
15.
Zurück zum Zitat Pagani FDJ, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: results of the endurance destination therapy trial. J Heart Lung Transpl. 2015;34(4):S9.CrossRef Pagani FDJ, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: results of the endurance destination therapy trial. J Heart Lung Transpl. 2015;34(4):S9.CrossRef
16.
Zurück zum Zitat Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transpl. 2009;28:881–7.CrossRef Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transpl. 2009;28:881–7.CrossRef
17.
Zurück zum Zitat Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg. 2012;42:319–23 (discussion 323).CrossRefPubMed Menon AK, Götzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg. 2012;42:319–23 (discussion 323).CrossRefPubMed
18.
Zurück zum Zitat Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241–50.CrossRefPubMed Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241–50.CrossRefPubMed
19.
Zurück zum Zitat Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.CrossRefPubMed Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.CrossRefPubMed
20.
Zurück zum Zitat van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Group AitSPEiCT-A-R. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109–13.CrossRefPubMed van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Group AitSPEiCT-A-R. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109–13.CrossRefPubMed
21.
Zurück zum Zitat Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the prospective randomized on-x valve anticoagulation clinical trial randomized food and drug administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202–10 (discussion 1210-1201).CrossRefPubMed Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the prospective randomized on-x valve anticoagulation clinical trial randomized food and drug administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147:1202–10 (discussion 1210-1201).CrossRefPubMed
22.
Zurück zum Zitat Bhimaraj A, Uribe C, Suarez EE. Physiological impact of continuous flow on end-organ function: clinical implications in the current era of left ventricular assist devices. Methodist DeBakey Cardiovasc J. 2015;11:12–7.CrossRefPubMedPubMedCentral Bhimaraj A, Uribe C, Suarez EE. Physiological impact of continuous flow on end-organ function: clinical implications in the current era of left ventricular assist devices. Methodist DeBakey Cardiovasc J. 2015;11:12–7.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Aggarwal A, Gupta A, Kumar S, Baumblatt JA, Pauwaa S, Gallagher C, et al. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO J. 2012;58:509–13.CrossRefPubMed Aggarwal A, Gupta A, Kumar S, Baumblatt JA, Pauwaa S, Gallagher C, et al. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO J. 2012;58:509–13.CrossRefPubMed
24.
Zurück zum Zitat Bogaev RC, Pamboukian SV, Moore SA, Chen L, John R, Boyle AJ, et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transpl. 2011;30:515–22.CrossRef Bogaev RC, Pamboukian SV, Moore SA, Chen L, John R, Boyle AJ, et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transpl. 2011;30:515–22.CrossRef
25.
Zurück zum Zitat Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63:880–8.CrossRefPubMed Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol. 2014;63:880–8.CrossRefPubMed
26.
Zurück zum Zitat Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transpl. 2014;33:35–43.CrossRef Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transpl. 2014;33:35–43.CrossRef
27.
Zurück zum Zitat Daneshmand MA, Krishnamoorthy A, Samsky MD, Felker GM, Pura JA, Lokhnygina Y, et al. Comparison of 2-year outcomes of extended criteria cardiac transplantation versus destination left ventricular assist device therapy using continuous flow. Am J Cardiol. 2015;116:573–9.CrossRefPubMed Daneshmand MA, Krishnamoorthy A, Samsky MD, Felker GM, Pura JA, Lokhnygina Y, et al. Comparison of 2-year outcomes of extended criteria cardiac transplantation versus destination left ventricular assist device therapy using continuous flow. Am J Cardiol. 2015;116:573–9.CrossRefPubMed
28.
Zurück zum Zitat Frazier OH, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, et al. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. Tex Heart Inst J. 2007;34:275–81.PubMedPubMedCentral Frazier OH, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, et al. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. Tex Heart Inst J. 2007;34:275–81.PubMedPubMedCentral
29.
Zurück zum Zitat Granfeldt H, Peterzén B, Hübbert L, Jansson K, Ahn H. A single center experience with the HeartMate II left ventricular assist device (lvad). Scand Cardiovasc J. 2009;43:360–5.CrossRefPubMed Granfeldt H, Peterzén B, Hübbert L, Jansson K, Ahn H. A single center experience with the HeartMate II left ventricular assist device (lvad). Scand Cardiovasc J. 2009;43:360–5.CrossRefPubMed
30.
Zurück zum Zitat Gregoric ID, Radovancevic R, Patel M, Fenik Y, Cohn WE, Frazier OH. Use of sealed grafts in the HeartMate II left ventricular assist device inflow and outflow conduits. ASAIO J. 2014;60:300–3.CrossRefPubMed Gregoric ID, Radovancevic R, Patel M, Fenik Y, Cohn WE, Frazier OH. Use of sealed grafts in the HeartMate II left ventricular assist device inflow and outflow conduits. ASAIO J. 2014;60:300–3.CrossRefPubMed
31.
Zurück zum Zitat Harvey L, Holley C, Roy SS, Eckman P, Cogswell R, Liao K, et al. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100:535–41.CrossRefPubMed Harvey L, Holley C, Roy SS, Eckman P, Cogswell R, Liao K, et al. Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era. Ann Thorac Surg. 2015;100:535–41.CrossRefPubMed
32.
Zurück zum Zitat Kato TS, Schulze PC, Yang J, Chan E, Shahzad K, Takayama H, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transpl. 2012;31:1–8.CrossRef Kato TS, Schulze PC, Yang J, Chan E, Shahzad K, Takayama H, et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transpl. 2012;31:1–8.CrossRef
33.
Zurück zum Zitat Katz MR, Dickinson MG, Raval NY, Slater JP, Dean DA, Zeevi GR, et al. Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers. Am J Cardiol. 2015;115:1254–9.CrossRefPubMed Katz MR, Dickinson MG, Raval NY, Slater JP, Dean DA, Zeevi GR, et al. Outcomes of patients implanted with a left ventricular assist device at nontransplant mechanical circulatory support centers. Am J Cardiol. 2015;115:1254–9.CrossRefPubMed
34.
Zurück zum Zitat Klodell CT, Massey HT, Adamson RM, Dean DA, Horstmanshof DA, Ransom JM, et al. Factors related to pump thrombosis with the HeartMate II left ventricular assist device. J Card Surg. 2015;30:775–80.CrossRefPubMed Klodell CT, Massey HT, Adamson RM, Dean DA, Horstmanshof DA, Ransom JM, et al. Factors related to pump thrombosis with the HeartMate II left ventricular assist device. J Card Surg. 2015;30:775–80.CrossRefPubMed
35.
Zurück zum Zitat Lahpor J, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37:357–61.PubMed Lahpor J, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37:357–61.PubMed
36.
Zurück zum Zitat Litzler PY, Smail H, Barbay V, Nafeh-Bizet C, Bouchart F, Baste JM, et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg. 2014;45:55–9 (discussion 59-60).CrossRefPubMed Litzler PY, Smail H, Barbay V, Nafeh-Bizet C, Bouchart F, Baste JM, et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg. 2014;45:55–9 (discussion 59-60).CrossRefPubMed
37.
Zurück zum Zitat Morgan JA, Brewer RJ, Nemeh HW, Gerlach B, Lanfear DE, Williams CT, et al. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J. 2014;60:284–9.CrossRefPubMed Morgan JA, Brewer RJ, Nemeh HW, Gerlach B, Lanfear DE, Williams CT, et al. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J. 2014;60:284–9.CrossRefPubMed
38.
Zurück zum Zitat Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–21.CrossRefPubMed Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312–21.CrossRefPubMed
39.
Zurück zum Zitat Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241–8.CrossRefPubMed Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241–8.CrossRefPubMed
40.
Zurück zum Zitat Saeed O, Shah A, Kargoli F, Madan S, Levin AP, Patel SR, et al. Antiplatelet therapy and adverse hematologic events during heart mate ii support. Circ Heart Fail. 2016;9:e002296.CrossRefPubMed Saeed O, Shah A, Kargoli F, Madan S, Levin AP, Patel SR, et al. Antiplatelet therapy and adverse hematologic events during heart mate ii support. Circ Heart Fail. 2016;9:e002296.CrossRefPubMed
41.
Zurück zum Zitat Salerno CT, Sundareswaran KS, Schleeter TP, Moanie SL, Farrar DJ, Walsh MN. Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events. J Heart Lung Transpl. 2014;33:809–15.CrossRef Salerno CT, Sundareswaran KS, Schleeter TP, Moanie SL, Farrar DJ, Walsh MN. Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events. J Heart Lung Transpl. 2014;33:809–15.CrossRef
42.
Zurück zum Zitat Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD, et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transpl. 2010;29:616–24.CrossRef Slaughter MS, Naka Y, John R, Boyle A, Conte JV, Russell SD, et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transpl. 2010;29:616–24.CrossRef
43.
Zurück zum Zitat Strüber M, Sander K, Lahpor J, Ahn H, Litzler PY, Drakos SG, et al. HeartMate II left ventricular assist device; early European experience. Eur J Cardiothorac Surg. 2008;34:289–94.CrossRefPubMed Strüber M, Sander K, Lahpor J, Ahn H, Litzler PY, Drakos SG, et al. HeartMate II left ventricular assist device; early European experience. Eur J Cardiothorac Surg. 2008;34:289–94.CrossRefPubMed
44.
Zurück zum Zitat van den Bergh WM, Lansink-Hartgring AO, van Duijn AL, Engström AE, Lahpor JR, Slooter AJ. Thromboembolic stroke in patients with a HeartMate II left ventricular assist device—the role of anticoagulation. J Cardiothorac Surg. 2015;10:128.CrossRefPubMedPubMedCentral van den Bergh WM, Lansink-Hartgring AO, van Duijn AL, Engström AE, Lahpor JR, Slooter AJ. Thromboembolic stroke in patients with a HeartMate II left ventricular assist device—the role of anticoagulation. J Cardiothorac Surg. 2015;10:128.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6:517–26.CrossRefPubMed Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6:517–26.CrossRefPubMed
46.
Zurück zum Zitat Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191–200.CrossRefPubMed Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191–200.CrossRefPubMed
47.
Zurück zum Zitat Bashir J, Legare JF, Freed DH, Cheung A, Rao V, Toma M. Multicentre canadian experience with the HeartWare ventricular assist device: concerns about adverse neurological outcomes. Can J Cardiol. 2014;30:1662–7.CrossRefPubMed Bashir J, Legare JF, Freed DH, Cheung A, Rao V, Toma M. Multicentre canadian experience with the HeartWare ventricular assist device: concerns about adverse neurological outcomes. Can J Cardiol. 2014;30:1662–7.CrossRefPubMed
48.
Zurück zum Zitat Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger H, et al. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg. 2012;93:810–5.CrossRefPubMed Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger H, et al. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. Ann Thorac Surg. 2012;93:810–5.CrossRefPubMed
49.
Zurück zum Zitat Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transpl. 2013;32:675–83.CrossRef Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transpl. 2013;32:675–83.CrossRef
50.
Zurück zum Zitat Strueber M, O’Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol. 2011;57:1375–82.CrossRefPubMed Strueber M, O’Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol. 2011;57:1375–82.CrossRefPubMed
51.
Zurück zum Zitat Arnaoutakis GJ, George TJ, Kilic A, Beaty CA, Weiss ES, Conte JV, et al. Risk factors for early death in patients bridged to transplant with continuous-flow left ventricular assist devices. Ann Thorac Surg. 2012;93:1549–54 (discussion 1555).CrossRefPubMedPubMedCentral Arnaoutakis GJ, George TJ, Kilic A, Beaty CA, Weiss ES, Conte JV, et al. Risk factors for early death in patients bridged to transplant with continuous-flow left ventricular assist devices. Ann Thorac Surg. 2012;93:1549–54 (discussion 1555).CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat John R, Kamdar F, Eckman P, Colvin-Adams M, Boyle A, Shumway S, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg. 2011;92:1593–9 (discussion 1599-1600).CrossRefPubMed John R, Kamdar F, Eckman P, Colvin-Adams M, Boyle A, Shumway S, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg. 2011;92:1593–9 (discussion 1599-1600).CrossRefPubMed
53.
Zurück zum Zitat Nascimbene A, Hernandez R, George JK, Parker A, Bergeron AL, Pradhan S, et al. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transpl. 2014;33:470–7.CrossRef Nascimbene A, Hernandez R, George JK, Parker A, Bergeron AL, Pradhan S, et al. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transpl. 2014;33:470–7.CrossRef
54.
Zurück zum Zitat Urban M, Pirk J, Szarszoi O, Besik J, Netuka I. Post-heart transplantation outcome of HeartMate II-bridged recipients requiring unplanned concomitant temporary right ventricular mechanical support. Interact CardioVasc Thorac Surg. 2015;20:372–8.CrossRefPubMed Urban M, Pirk J, Szarszoi O, Besik J, Netuka I. Post-heart transplantation outcome of HeartMate II-bridged recipients requiring unplanned concomitant temporary right ventricular mechanical support. Interact CardioVasc Thorac Surg. 2015;20:372–8.CrossRefPubMed
55.
Zurück zum Zitat Whitson BA, Eckman P, Kamdar F, Lacey A, Shumway SJ, Liao KK, et al. Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients. Ann Thorac Surg. 2014;97:2097–103.CrossRefPubMed Whitson BA, Eckman P, Kamdar F, Lacey A, Shumway SJ, Liao KK, et al. Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients. Ann Thorac Surg. 2014;97:2097–103.CrossRefPubMed
56.
Zurück zum Zitat Saeed O, Jermyn R, Kargoli F, Madan S, Mannem S, Gunda S, et al. Blood pressure and adverse events during continuous flow left ventricular assist device support. Circ Heart Fail. 2015;8:551–6.CrossRefPubMed Saeed O, Jermyn R, Kargoli F, Madan S, Mannem S, Gunda S, et al. Blood pressure and adverse events during continuous flow left ventricular assist device support. Circ Heart Fail. 2015;8:551–6.CrossRefPubMed
57.
Zurück zum Zitat Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, et al. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transpl. 2014;33:88–93.CrossRef Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, et al. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transpl. 2014;33:88–93.CrossRef
58.
Zurück zum Zitat Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Borgi J, Hodari A, et al. Lessons learned from 150 continuous-flow left ventricular assist devices: a single institutional 7 year experience. ASAIO J. 2015;61:266–73.CrossRefPubMed Tsiouris A, Paone G, Nemeh HW, Brewer RJ, Borgi J, Hodari A, et al. Lessons learned from 150 continuous-flow left ventricular assist devices: a single institutional 7 year experience. ASAIO J. 2015;61:266–73.CrossRefPubMed
Metadaten
Titel
Stroke and Intracranial Hemorrhage in HeartMate II and HeartWare Left Ventricular Assist Devices: A Systematic Review
verfasst von
Sung M. Cho
Nader Moazami
Jennifer A. Frontera
Publikationsdatum
21.03.2017
Verlag
Springer US
Erschienen in
Neurocritical Care / Ausgabe 1/2017
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-017-0386-7

Weitere Artikel der Ausgabe 1/2017

Neurocritical Care 1/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.